Biomarker platform is among the first validated applications of Genialis’ machine learning approach to help predict patient responses to targeted oncology therapies.

Genialis, a leader in applied data science for the development of precision medicines, today announced its contributions to a biomarker platform and panel that demonstrated prognostic capabilities for recurrence-free and overall survival in colorectal cancer (CRC). In a poster presentation (#348) at the virtual AACR Annual Meeting 2021: Discovery Science Driving Clinical Breakthroughs, Genialis helped support the evaluation of OncXerna Therapeutic’s Xerna™ platform and TME Panel, an RNA-based pan-tumor biomarker, in two gene expression datasets—one from 566 patients and the other from 93 patients. This novel diagnostic and prognostic platform uses a proprietary set of biomarker genes, RNA-based gene expression data, and machine learning to classify patients based on the dominant biologies of the tumor microenvironment.

Read the press release in its entirety here.

Share this story, choose your platform!